Skip to main content
Erschienen in: Medical Oncology 6/2018

01.06.2018 | Original Paper

Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors

verfasst von: Yuki Maruyama, Takuya Sadahira, Yosuke Mitsui, Motoo Araki, Koichiro Wada, Ryuta Tanimoto, Yasuyuki Kobayashi, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu

Erschienen in: Medical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Bleomycin pulmonary toxicity (BPT) has been well described in patients with germ cell tumors treated with bleomycin etoposide and cisplatin chemotherapy (BEP). To assess the prognostic impact of BPT, we retrospectively identified 52 patients who underwent bleomycin etoposide and cisplatin chemotherapy from 2008 to 2017 in our institution, and evaluated the risk factors of BPT and its effect on prognosis. Patients who had received chemotherapy at another institution were excluded. BPT was defined as bleomycin discontinuation in response to pulmonary function test decline, pulmonary symptoms, or interstitial pneumonia on computed tomography without infection. We divided the patients into two groups according to this definition: BPT and non-BPT. Their median age was 34.2 years, and their median body mass index was 22.8 kg/m2. Twenty patients had a smoking history, 37 were diagnosed with non-seminoma, and 20 had lung metastasis. The median cumulative bleomycin dose was 270 mg/body. Fifteen patients were classified into the BPT group and 37 into the non-BPT group. Only body mass index < 22 was identified as a predictor of BPT in multivariable logistic models. Age or use of granulocyte-colony stimulating factor did not have a significant impact. Kaplan–Meier analysis revealed that the presence of BPT had no significant impact on either 5-year overall survival or progression-free survival. Lower body mass index can increase the risk of BPT in patients with germ cell tumors undergoing BEP. However, discontinuation of bleomycin with BPT does not adversely influence the survival outcomes.
Literatur
1.
Zurück zum Zitat Loehrer P, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470–6.CrossRefPubMed Loehrer P, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470–6.CrossRefPubMed
2.
Zurück zum Zitat de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837–43.CrossRefPubMed de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837–43.CrossRefPubMed
3.
Zurück zum Zitat International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594–603.CrossRef International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594–603.CrossRef
4.
Zurück zum Zitat Blum RH, Carter SK, Aqre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer. 1973;31:903–14.CrossRefPubMed Blum RH, Carter SK, Aqre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer. 1973;31:903–14.CrossRefPubMed
5.
Zurück zum Zitat O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–6.CrossRefPubMed O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–6.CrossRefPubMed
6.
Zurück zum Zitat Levi JA, Raghavan D, Thompson D, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993;11:1300–5.CrossRefPubMed Levi JA, Raghavan D, Thompson D, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993;11:1300–5.CrossRefPubMed
7.
Zurück zum Zitat Van Barneveld P, Van der Mark DT, Sleijfer T, et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis. 1984;130:1078–81.PubMed Van Barneveld P, Van der Mark DT, Sleijfer T, et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis. 1984;130:1078–81.PubMed
8.
Zurück zum Zitat Simpson A, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061–6.CrossRefPubMedPubMedCentral Simpson A, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061–6.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Sun HL, Atenafu EG, Tsang R, et al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma. 2017;58:2607–14.CrossRefPubMed Sun HL, Atenafu EG, Tsang R, et al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma. 2017;58:2607–14.CrossRefPubMed
10.
Zurück zum Zitat Martin WG, Ristow KM, Habermann TM, Colqan JP, Witziq TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–20.CrossRefPubMed Martin WG, Ristow KM, Habermann TM, Colqan JP, Witziq TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–20.CrossRefPubMed
12.
Zurück zum Zitat Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102:1253–62.CrossRefPubMed Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102:1253–62.CrossRefPubMed
13.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
14.
Zurück zum Zitat Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with oud without granulocyte colony stimulating factor. Chest. 1997;111:657–60.CrossRefPubMed Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with oud without granulocyte colony stimulating factor. Chest. 1997;111:657–60.CrossRefPubMed
15.
Zurück zum Zitat Roncolate FT, Chatfield M, Hougton B. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Intern Med J. 2016;46:893–8.CrossRef Roncolate FT, Chatfield M, Hougton B. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Intern Med J. 2016;46:893–8.CrossRef
16.
Zurück zum Zitat McKeage MJ, Evans BD, Atkinson C, Perez D, Forgeson GV, Dady P. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol. 1990;8:779–83.CrossRefPubMed McKeage MJ, Evans BD, Atkinson C, Perez D, Forgeson GV, Dady P. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol. 1990;8:779–83.CrossRefPubMed
17.
Zurück zum Zitat Bell MR, Meredith DJ, Gill OG. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Aust N Z J Med. 1985;15:235 – 40.CrossRefPubMed Bell MR, Meredith DJ, Gill OG. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Aust N Z J Med. 1985;15:235 – 40.CrossRefPubMed
18.
Zurück zum Zitat Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol. 1990;8:765–7.CrossRefPubMed Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol. 1990;8:765–7.CrossRefPubMed
19.
Zurück zum Zitat Shamash J, Sarker SJ, Huddart R, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol. 2017;28:1333–8.CrossRefPubMed Shamash J, Sarker SJ, Huddart R, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol. 2017;28:1333–8.CrossRefPubMed
20.
Zurück zum Zitat Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12:313–7.CrossRefPubMed Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12:313–7.CrossRefPubMed
21.
Zurück zum Zitat Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–20.CrossRefPubMed Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–20.CrossRefPubMed
23.
Zurück zum Zitat Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286–92.CrossRefPubMed Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286–92.CrossRefPubMed
26.
Zurück zum Zitat Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer. 1985;56:2411–5.CrossRefPubMed Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer. 1985;56:2411–5.CrossRefPubMed
27.
Zurück zum Zitat Necchi A, Miceli R, Oualla K, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Cenitourin Cancer. 2017;15:213–20.CrossRef Necchi A, Miceli R, Oualla K, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Cenitourin Cancer. 2017;15:213–20.CrossRef
28.
Zurück zum Zitat Jankilevich G. BEP versus EP for treatment of metastatic germ-cell tumours. Lancet Oncol. 2004;5:146–7.CrossRefPubMed Jankilevich G. BEP versus EP for treatment of metastatic germ-cell tumours. Lancet Oncol. 2004;5:146–7.CrossRefPubMed
29.
Zurück zum Zitat Jones RH, Vasey PA. Part II: testicular cancer—management of advanced disease. Lancet Oncol. 2003;4:738–47.CrossRefPubMed Jones RH, Vasey PA. Part II: testicular cancer—management of advanced disease. Lancet Oncol. 2003;4:738–47.CrossRefPubMed
30.
Zurück zum Zitat Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917–24.CrossRefPubMed Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917–24.CrossRefPubMed
Metadaten
Titel
Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors
verfasst von
Yuki Maruyama
Takuya Sadahira
Yosuke Mitsui
Motoo Araki
Koichiro Wada
Ryuta Tanimoto
Yasuyuki Kobayashi
Masami Watanabe
Toyohiko Watanabe
Yasutomo Nasu
Publikationsdatum
01.06.2018
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 6/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1140-5

Weitere Artikel der Ausgabe 6/2018

Medical Oncology 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.